Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific ( (BSX) ) has issued an update.
On October 22, 2025, John E. Sununu announced he will not seek re-election to Boston Scientific‘s Board of Directors at the 2026 Annual Meeting. Sununu, who has been a board member since 2009, will continue his roles until then, with his decision not stemming from any disagreement with the company. The board will assess the need for new directors following his departure.
The most recent analyst rating on (BSX) stock is a Buy with a $125.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Outperform.
Boston Scientific’s strong financial performance and positive earnings call are the primary drivers of its stock score. While technical analysis shows mixed signals, the upward trend in stock price supports a positive outlook. However, the high P/E ratio suggests caution regarding valuation.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific is a company in the medical device industry, focusing on the development and manufacturing of innovative medical solutions. Their primary products include devices used in interventional medical specialties, such as cardiology, endoscopy, and urology, with a market focus on improving patient outcomes and advancing healthcare.
Average Trading Volume: 8,600,132
Technical Sentiment Signal: Strong Buy
Current Market Cap: $148B
For an in-depth examination of BSX stock, go to TipRanks’ Overview page.